Mr. Elliott brings two decades of senior leadership experience in the medical diagnostics industry, including 8 years at Exact Sciences Corp., where he served as chief financial officer from November 2016 to May 2024 and chief operating officer from April 2021 to May 2023. While at Exact Sciences, he was responsible for finance, strategy and business development, helping to effectively scale the business, achieving high revenue growth during his tenure, and overseeing numerous acquisitions and venture investments.

Prior to joining Exact Sciences, Mr. Elliott was a senior equity research analyst at Robert W. Baird & Co. where he covered health care companies, including companies in the diagnostics and life science tools industry. He brings to Quanterix a breadth of business strategy experience within the life sciences industry.

Mr. Elliott earned a Bachelor of Science in business administration from the University of Illinois at Urbana-Champaign and an M.B.A. from the University of Chicago Booth School of Business. Mr. Elliott is a CFA^® charterholder.

“We’re pleased to welcome Jeff to our board of directors at an exciting time for the company. As Quanterix actively builds the infrastructure for Alzheimer’s Disease testing to ensure access to early diagnosis, Jeff’s experience in scaling Exact Sciences’ operations and financial experience will be invaluable,” said Masoud Toloue, CEO of Quanterix.

“Jeff is a wonderful addition to our Board, and we look forward to leveraging his expertise in the industry as Quanterix continues to grow,” said Martin Madaus, Chairman of the Board.

“It is a pivotal time in life sciences and diagnostics, and I’m thrilled to join the Quanterix board amid great innovation and opportunity,” said Mr. Elliott. “The mission to scale Quanterix’s Simoa technology is bold and ambitious, and I am excited to apply my experience to help the company achieve this goal and support continued innovation.”

To learn more about Quanterix’s Simoa^® technology, visit: https://www.quanterix.com/simoa-technology/.

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post Jeffrey Elliott Appointed to Quanterix’s Board of Directors first appeared on AI-Tech Park.

InsideTracker, the leading personalized health platform, today announced the addition of its newest feature: Ask InsideTracker, an AI-powered language model that allows members to explore wellness topics and find real-time solutions to health challenges.

Ask InsideTracker is built on OpenAI’s GPT-4, so it’s familiar and easy to use. But it’s filtered through InsideTracker’s extensive library of educational material, which allows it to cut through the noise of unscientific health advice.

When members query Ask InsideTracker, they’re having a conversation with a massive library of articles written and reviewed by InsideTracker experts in nutrition, exercise physiology, preventive health, and biology. That leads to science-backed answers and trustworthy information on health, longevity, and biomarkers. Members can ask, “Why do I have high iron with low ferritin?” or “Which biomarkers should I focus on improving if my ultimate goal is to increase my VO2max?”

As a large language model (LLM), Ask InsideTracker will supplement InsideTracker’s personalized recommendations in real time. It can go deep on individual health topics, or it can simplify complex advice to meet the member where they are in their health journey.

“InsideTracker has always been ahead of the game with AI,” said Renée Deehan, PhD, InsideTracker’s Senior Vice President of Science and AI. “For years, the driving force of our recommendation engine has been a type of AI called ‘knowledge representation and reasoning.’ Ask InsideTracker is our way of doubling-down on our commitment to AI. As our first LLM-based product feature, it allows members to speak directly with more than a decade’s worth of education material written by InsideTracker experts.”

As science evolves, so does Ask InsideTracker. InsideTracker is constantly updating its educational library, so Ask InsideTracker will always have access to the most current research and information.

“With the Ask InsideTracker model ingrained into our app and desktop interfaces, I’m excited for our members to gain access to pertinent information surrounding biomarkers, nutritional information, and general health guidance faster and easier than ever before,” said Gil Blander, PhD, Founder and Chief Scientific Officer. “I am hopeful that our members will leave the conversations with our Ask InsideTracker feature more informed and excited about how they can optimize their health through tangible and actionable changes.”

Future versions of Ask InsideTracker will allow a secure experience where members can engage with their own blood, DNA, and fitness tracker data. The Ask InsideTracker feature is currently only available to members. They can access it any time they’re logged in to the InsideTracker platform.

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post InsideTracker Launches Innovative “Ask InsideTracker” AI Chat Feature first appeared on AI-Tech Park.

NeuroTherapia, Inc., a clinical-stage company and Cleveland Clinic Innovations portfolio company focused on developing therapies for neurodegenerative diseases, announced today the first closing of its Series B financing with $12.3M in funding. The Series B round, led by Cleveland Clinic, includes all previous investors, Brain Trust Accelerator Fund II, Dolby Family Ventures and the Alzheimer’s Drug Discovery Foundation (ADDF) as well as new investors, Foundation for a Better World and CRUINT. NeuroTherapia is using this funding primarily for the continued clinical development of NTRX-07, an orally available cannabinoid receptor agonist, for the treatment of Alzheimer’s disease (AD). The company will continue to raise additional funds for its second close in six months, which will enable development of a recently discovered second generation molecule for a separate indication in which neuroinflammation plays a major role.

 “We were pleased with the Phase 1b trial results that demonstrated a trend toward cognitive benefits in Alzheimer’s disease and wanted to continue its development as rapidly as possible,” commented Joseph Rich, JD, MBA, Senior Director, Cleveland Clinic Innovations, and lead investor representative in this financing. “We believe that the Company’s planned Phase 2a trial has the potential to not only demonstrate the ability of NTRX-07 to inhibit neuroinflammation, but it could also lead to an improvement in biomarkers of cognitive function in patients with Alzheimer’s disease.”

Coincident with the financing, the company welcomes Adam Hoffman to its Board of Directors as an Observer. Mr. Hoffman is an experienced investor and entrepreneur, currently serving as President of Foundation for a Better World. Mr. Hoffman joins Mr. Reher, who will continue to serve as Chairman of the Board, Tony Giordano, Ph.D., NeuroTherapia’s President and CEO, and Joseph Rich and Jim Ellis from Cleveland Clinic and Akhil Saklecha, M.D., the CSO at Danaher, on the Board. In addition, Meriel Owen, Ph.D., Director of Search and Evaluation at the ADDF, serves as an Observer.

“We are extremely fortunate to have the continued support of our previous investors and to add new investors with significant AD experience,” said Dr. Giordano. “The Board has provided invaluable insights over the past 4+ years and I am excited to continue to work with them to advance NTRX-07 for treating AD.”

In addition to the Phase 2a trial, NeuroTherapia will use funding from this financing to study NTRX-07 in a preclinical model of ARIA (a significant side effect observed with administration of therapeutic monoclonal antibodies) in combination with therapeutic monoclonal antibodies. Based on its mechanism of action, NTRX-07 may reduce or prevent the ARIA side effect associated with monoclonal antibody treatment and/or improve the benefits of these therapies. A demonstration of activity in the preclinical ARIA study could lead to subsequent trials where NTRX-07 is used in combination with the therapeutic monoclonal antibodies to provide additional patient benefits. The company has also identified second-generation molecules that will be advanced for other indications associated with increased neuroinflammation, such as pain, Parkinson’s disease or ALS.

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post NeuroTherapia Raises $12.3M in the First Close of its Series B Financing first appeared on AI-Tech Park.

Partnership Expands Reach of C2N’s Precivity Blood Tests in Over 75 Countries to Transform Alzheimer’s Disease Early Diagnosis and Research

 Unilabs (“Unilabs”), a leading international provider of diagnostic services, and C2N Diagnostics, LLC (“C2N”),  a pioneer in advanced diagnostic solutions in the field of Alzheimer’s disease (AD) and related neurological disorders, today announced a major milestone in brain health diagnostics and research across Europe and beyond.

Unilabs and C2N have signed a multi-year partnership agreement that will increase access to C2N’s Precivity portfolio of blood tests on an exclusive basis in Europe, including Norway, Switzerland, and the United Kingdom. The agreement will also provide access in Peru, Saudi Arabia, and the United Arab Emirates.

“Alzheimer’s disease is on the rise, making it essential to innovate by offering less invasive and more accessible diagnostic procedures for patients,” said Unilabs’ Head of Innovation Dr. Rahul Chaudhary.  “All too often, diagnosing Alzheimer’s has been painful, invasive and expensive. This partnership will transform the diagnostic experience for patients with cognitive concerns while revolutionizing early diagnosis, and research efforts, and positively impacting long-term outcomes.”

He continued, “C2N’s Precivity portfolio of blood tests and its innovative biomarker pipeline offer the highest performance precision tools in the industry¹. We expect these innovations to appeal to healthcare providers in Europe, the Gulf Region and Latin America who rely on us, and to our biopharma collaborators who are developing new therapies. Patients worldwide deserve access to an early diagnosis, leveraging personalized medicine tools that can enable better treatment decisions and activate long-term disease prevention strategies. We are confident these tests can help in achieving better outcomes for patients, as we continue in our mission to power health and maximize life.”

C2N’s Precivity portfolio of blood tests aid healthcare providers and researchers in the detection of amyloid plaques and neurofibrillary “tau” tangles in the brain, which are pathological hallmarks of Alzheimer’s disease. These tests also help to inform medical management and treatment decisions based on the underlying causes of dementia.

This strategic partnership also plans to facilitate a technology transfer of C2N’s proprietary portfolio of Alzheimer’s blood biomarkers to deliver a Unilabs testing network across Europe, ensuring Precivity testing can be performed at qualified healthcare institutions with the same quality, consistency and accuracy currently delivered at C2N’s central CAP/CLIA lab in St. Louis, Mo.

Both companies believe this partnership will transform global Alzheimer’s disease diagnosis for patients with cognitive concerns or at high risk of future AD or AD-related dementias.

Healthcare Sector Eager for Easy-to-Access, Less Invasive Tests

C2N previously announced in 2020 that the PrecivityAD® blood test achieved the CE Mark from the European Union (EU) and also has In Vitro Diagnostic Regulation legacy device status under Regulation (EU) 2017/746, which allows for commercial availability in the EU as an in vitro diagnostic to aid in the evaluation of patients with mild cognitive impairment or dementia. In addition, the United Kingdom’s Medicines and Healthcare Products Regulatory Agency approved the PrecivityAD blood test as an in vitro diagnostic to aid in the diagnosis of Alzheimer’s disease.

C2N CEO Dr. Joel Braunstein said, “The sobering impact of Alzheimer’s disease reaches beyond any one country’s borders and that’s why it’s vital we respond to the global interest in our Precivity blood tests. We believe this collaboration allows for the acceleration of equitable access to the highest quality blood biomarkers that can aid in the diagnosis of Alzheimer’s disease. To date, we’ve secured other international arrangements and now, we’re very proud to enter this multi-faceted strategic affiliation with Unilabs, an organization that places a premium on quality in testing and in personalized diagnostics for Alzheimer’s disease.”

The PrecivityAD2 and PrecivityAD blood tests use highly sensitive and specialized laboratory technologies to identify and measure certain proteins that are found in the blood and that are known to be associated with the presence of brain amyloid plaques, one of the brain pathology findings of Alzheimer’s disease. The main test result is a clinically validated score that determines a patient’s likelihood category for the presence of brain amyloid plaques. Like other tests that evaluate for brain amyloid pathology in clinical patients, such as amyloid PET scan or cerebrospinal fluid (CSF) testing, the Precivity blood tests can be used by healthcare providers to interpret the test results, along with other medical information.

The tests are intended for use in patients 55 years and older with signs or symptoms of mild cognitive impairment or dementia. These tests are only available for order by qualified healthcare providers.

C2N and Unilabs expect the Precivity portfolio of blood tests will become available to Unilabs customers over the coming months, depending on geographic region.

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post C2N Diagnostics and Unilabs Announce Global Partnership first appeared on AI-Tech Park.

With the increasing prevalence of cognitive impairment, including Alzheimer’s and other dementias, there is a critical need for innovative solutions that bridge the gap between assessment, diagnosis, and actionable care. The combined solution simplifies the complexities of clinical workflows, offering precise insights for healthcare providers to deliver more effective care across their patient populations.

Closing Care Gaps with Advanced Technologies

The collaboration between uMethod Health and Linus Health empowers clinicians with:

• Comprehensive cognitive assessments: Linus Health’s state-of-the-art digital health platform offers advanced cognitive assessments that leverage artificial intelligence to provide accurate and timely evaluations of memory and executive function.
• Personalized care planning: uMethod Health’s innovative platform creates individualized care plans based on a patient’s unique cognitive profile, biomarkers, and medical history, ensuring tailored interventions and treatments.
• Streamlined workflows: The combined strength of both platforms seamlessly guides clinicians from assessment to care planning, reducing administrative burdens and enhancing clinical efficiency.

Empowering Patients and Clinics

Both uMethod Health and Linus Health are committed to equipping clinicians and patients with the tools they need to navigate complex cognitive care with the integrated solution, which offers:

• Enhanced patient engagement: Patients gain access to clear, personalized care plans that empower them to take an active role in their cognitive health.
• Help improve clinical outcomes: Clinicians benefit from precise, data-driven insights that support early diagnosis and effective intervention.
• Greater accessibility: The partnership offers cutting-edge cognitive care solutions to a broad range of patients and healthcare providers, regardless of their geographic location.

“By combining Linus Health’s advanced cognitive assessment capabilities with uMethod’s personalized care planning, we can help identify individuals in need earlier and significantly enhance the management of their cognitive disorders–ultimately improving patient outcomes,” said David Bates, PhD, Linus Health CEO and co-founder.

Vik Chandra, CEO of uMethod Health, said: “This partnership represents a significant step forward in cognitive care. Together, uMethod and Linus Health are simplifying the complexities of cognitive care workflows and providing clinicians with the tools they need for informed, precise decisions that benefit ALL their patients.”

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post uMethod Health announced collaboration with Linus Health first appeared on AI-Tech Park.

In the last five years, the healthcare industry has seen an explosion of data, reflecting not just a patient’s healthcare encounters, but also novel data sources such as genomic and biomarker data. These datasets can provide a wealth of clinical and scientific information, but their siloed nature has made it difficult for data users to determine which datasets are most appropriate for their unique enterprise needs. Healthcare and life sciences user demand for this type of fit-for-purpose data requires a technology solution at scale.

“We’re thrilled to be expanding our relationship with AWS in pursuit of providing our customers with a secure and scalable solution for leveraging healthcare data across the enterprise. We’ve heard from our customers that better data discovery and utilization will empower them to answer their most strategic questions across drug development, clinical research, and population health use cases,” said Kyle Armbrester, Datavant CEO.  

This strategic collaboration expands upon Datavant’s and AWS’ existing relationship, which created Datavant Connect tokenization technology as a compatible offering for AWS. With this SCA, Datavant will build additional capabilities leveraging AWS Clean Rooms – a service that helps companies collaborate with partners without sharing raw data – to provide a “no underlying data movement” solution for pre-sales feasibility analyses between data sources and data buyers.

With an initial focus on tools for data discovery and data partner assessment, the collaboration will accelerate the process of finding and evaluating fit-for-purpose datasets. This enables a more efficient and secure approach for healthcare data discovery, evaluation, and analytics.

“The majority of healthcare data today is still not being used to the fullest extent possible, due to strategic, privacy, and data wrangling challenges,” said Arnaub Chatterjee, Datavant President and GM of Life Sciences, Ecosystem, and Public Sector. “By delivering Datavant Connect capabilities directly where data resides, our customers will benefit from enhanced data security and faster time to insight.”

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post Datavant, AWS Ink SCA for Cloud-First Healthcare Data Solutions first appeared on AI-Tech Park.

CND Life Sciences (CND), a medical technology company pioneering the development of cutaneous neurodiagnostic tests and associated biomarker services, today announced the expansion of its leadership team by welcoming four new executives. Hernan Lopez joins CND as Chief Operating Officer, Kathryn Van Wie as Vice President of Strategy & Business Development, Annemarie Benton as Vice President of Market Access, and Bryan May as Vice President of Information Technology.

“We are thrilled to welcome this outstanding group of world-class leaders to the CND executive team,” said Richard J. Morello, Chief Executive Officer of CND Life Sciences. “With their deep breadth of experience in healthcare, medical devices, life science, and biotech, we are well-positioned to expand our work helping physicians and patients detect and treat neurodegenerative diseases easier, safer, and more effectively than ever before.”

As Chief Operating Officer, Hernan Lopez will provide strategic leadership and drive operational excellence across a range of functional areas within CND. He has an unprecedented track record and nearly 20 years of experience in medical device and life sciences companies. Prior to joining CND, Hernan was the Executive Vice President of Operations at GT Medical Technology, where he successfully brought an innovative medical device for the treatment of brain cancer to market. Prior to GT Medical Technologies, Hernan successfully managed explosive growth venture-backed company operations with successful exits, supported post-merger integrations, and worked in several operations roles in contract manufacturing organizations as well as multinational medical device companies such as Boston Scientific.

Regarding his new appointment, Hernan Lopez remarked, “I am excited to join CND as a true pioneer in the field of neurodegenerative diseases. I look forward to collaborating with CND’s talented and dedicated team to advance our patient mission during this next phase of growth.”

Kathryn Van Wie, Vice President of Strategy & Business Development, will focus on key strategic initiatives including CND’s biomarker capabilities for pharmaceutical clinical trials, international market expansion, and growing partnerships leveraging complementary technologies. Kathryn is an attorney who spent a decade at Vertex Pharmaceuticals as Corporate Counsel and subsequently in US Marketing and as Chief of Staff in Commercial Strategy and Operations.

Annemarie Benton, Vice President of Market Access, will oversee the development and execution of CND’s market access and payer engagement strategies. Annemarie brings more than 17 years of experience in the life sciences and advanced diagnostic laboratory industries. She began her career as a molecular scientist and leverages her clinical background to advocate for the adoption of precision medicine solutions by navigating the evolving payer landscape. Prior to joining CND, Annemarie was Head of Managed Care at Bionano and led the payer relations and managed care department at Caris Life Sciences.

Bryan May, Vice President of Information Technology, will be responsible for all IT functions. With over 25 years of experience across diverse industries including healthcare, distribution, supply chain, and contract manufacturing, Bryan brings a proven track record of driving digital transformation, optimizing IT infrastructure, and implementing solutions to enhance operational efficiency and strategic growth. Prior to joining CND, Bryan worked at Atara Biotherapeutics where he supported infrastructure and cloud services across 3 sites. Before that, he served as the Senior Director of Infrastructure Services and Cloud Engineering at McKesson for 15 years.

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post CND Life Sciences Expands Leadership with Four Key Exec Appointments first appeared on AI-Tech Park.

Proscia^®, a global leader in AI-enabled pathology solutions for precision medicine, has partnered with Nucleai, a leading spatial AI biomarker company that maps protein expression and cellular interactions within tissue samples to predict therapeutic outcomes. At the center of the collaboration, the companies will integrate Nucleai’s predictive biomarker solutions into Proscia’s Concentriq^® software platform and make them available as part of Proscia’s precision medicine AI portfolio to better inform patient care.

The rise of precision medicine is putting new pressures on diagnostic laboratories to tap into their pathology data, as whole slide images are among the best representations of disease. Nucleai’s predictive biomarkers create an AI-guided spatial map of a patient biopsy that helps these laboratories to target recruitment and optimize execution for the clinical trials they support. The same spatial mapping will also enable Nucleai’s applications to serve as companion diagnostics that match patients to the most effective treatment. Nucleai’s high-quality, scalable AI spatial and digital pathology solutions are adopted by over 60 percent of the top 20 biopharma companies in the world.

“Today’s advanced therapies require advanced diagnostics,” said David West, Proscia’s CEO. “Software-based approaches, made possible by the proliferation of pathology imaging and AI capabilities, offer a radical new option for bringing these treatments to patients. By expanding our AI pipeline with Nucleai’s solutions, we will elevate the role of the diagnostic laboratory in precision medicine to benefit drug developers, pathologists, and patients alike.”

Proscia’s Concentriq is an enterprise pathology platform for all digital pathology data and AI-enabled workflows from discovery to diagnosis. With a growing portfolio of applications from Proscia, Proscia’s customers, and leading third parties, it is addressing the widest range of AI use cases on a single platform. Concentriq is used by 14 of the top 20 pharmaceutical companies and major diagnostic laboratories worldwide.

“Together, Proscia and Nucleai will enable more pathologists and clinicians to convert the complex data from patient biopsies into precise, actionable insights that can drive better clinical trial and diagnostic decisions,” said Avi Veidman, Nucleai’s CEO. “Our partnership holds tremendous promise for advancing next-generation treatment modalities like ADCs, multispecifics, immunotherapy, and combination therapies. With the recent deployment of our technology to aid patient enrollment for an active trial and the growing need for AI-powered biomarkers across trials and diagnostics, this partnership represents a significant step forward in deploying our solutions, at scale. Together with Proscia, we can fundamentally improve the efficiency and effectiveness of introducing groundbreaking treatments and advancing patient care.”

Along with today’s news, Nucleai joins the Proscia Ready partner alliance. Proscia Ready is made up of solution providers helping diagnostic laboratories and life sciences organizations accelerate the scaled adoption of digital pathology with confidence through a comprehensive approach.

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post Proscia & Nucleai partner to broaden access to AI predictive biomarkers first appeared on AI-Tech Park.

Nucleai, a spatial AI biomarker company that deciphers cellular conversations and maps cellular interactions within tissue samples to predict therapeutic outcomes, announced today the expansion of its executive leadership team with the appointment of Vikas Ahuja as Vice President of Strategic Partnerships. With over 20 years of experience in life sciences, Ahuja will be responsible for building an ecosystem of partners—including diagnostic companies, contract research organizations (CROs), assay and instrument vendors, and software companies—that will enable Nucleai’s AI platform to be deployed at scale for late-stage clinical trials and diagnostic applications.

“Vikas has a wealth of experience and knowledge in business development across various sectors within the life sciences industry and is a perfect addition to our team,” said Avi Veidman, CEO of Nucleai. “Our AI spatial technology is currently used in an active clinical trial to aid patient selection. We’re seeing an increasing need for AI spatial biomarkers to support the rapidly growing pipeline of next-generation treatments, including antibody-drug conjugates, multi-specifics, and novel checkpoint inhibitors. Vikas’ proven track record of fostering strategic alliances and driving global growth initiatives speaks volumes about his expertise in building partnerships to scale the deployment of novel diagnostics. We are thrilled to welcome him to Nucleai, where his insights and leadership will accompany our mission to power the next generation of precision therapeutics with AI-driven spatial biomarkers and diagnostics.”

Before joining Nucleai, Ahuja held a leadership role as Vice President of Business Development & Strategy at Ambry Genetics, where he spearheaded corporate strategy, M&A activities, and licensing initiatives, and oversaw International business segments. He also led the establishment of international partnerships, strategically forging alliances across regions like Latin America, the Middle East, Southeast Asia, China, and Australia at Mallinckrodt Pharmaceuticals.

“This role presents a tremendous opportunity to leverage my experience in building impactful collaborations across the life sciences sector,” said Ahuja. “The recent partnership with GoPath Diagnostics is a prime example of how strategic alliances can advance our mission of transforming patient care through advanced AI-driven spatial biomarkers. I look forward to fostering similar partnerships to enhance our relationships with large commercial and diagnostic companies, propelling our innovative platform to new heights and ultimately improving patient outcomes.”

Ahuja earned his MBA from The Wharton School of the University of Pennsylvania and his MS in Chemical Engineering from Imperial College, London.

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post Nucleai Appoints Vikas Ahuja as VP of Strategic Partnerships first appeared on AI-Tech Park.

Fountain Life, an advanced diagnostics, longevity and preventative health company, today announced Fountain Life CORE, its new membership package that provides an entry point to longevity and proactive health optimization for millions of Americans.

Fountain Life is committed to enhancing and preserving each member’s quality of life throughout the aging process by identifying potential issues before they become serious health concerns. The company is creating a new kind of predictive, preventive, personalized, and data-driven healthcare. By leveraging informed AI technologies and advanced diagnostic testing to identify conditions such as cancer, cardiac, metabolic, and neurodegenerative disease at the earliest stages, Fountain Life empowers individuals to live a longer, healthier, and optimized life. 

At $2995 per year, the Fountain Life CORE membership provides a pathway for new members to prioritize their health and get started on a proactive journey toward optimized health and longevity. CORE includes quarterly blood tests that analyze dozens of biomarkers, uncovering deep insights about a member’s cardiovascular health, metabolic health, hormonal balance, inflammatory response, and nutrition levels. Each test is followed by a televisit review with a Fountain Life longevity physician who creates a customized optimization plan based on the member’s biomarker results, lifestyle, environment, and genetic factors. Between physician visits, CORE members work with a Fountain Life certified health coach to achieve the goals laid out in the customized health plan. Fountain Life’s approach is rooted in the principles of functional medicine, which includes a balance of treating symptoms while also uncovering the underlying root cause of health issues.

“Fountain Life is fundamentally changing the approach to health and longevity. We recognize that traditional primary care physicians often fall short in fully assessing health diagnostics to optimize well-being and promote longevity and typically don’t employ the root cause, functional medicine approach. With our new CORE membership, we’re opening doors to proactive health for everyone while also extending our focus on longevity. This initiative embodies our commitment to equip everyone with the resources needed for proactive health management and longevity promotion, including access to some of the most advanced diagnostic tools available.” William Kapp, MD, CEO & Co-Founder, Fountain Life.

The Fountain Life CORE membership is easily and conveniently managed through an exclusive Fountain Life mobile app experience.  Members can schedule blood draws and appointments with Fountain Life physicians and health coaches, monitor their test results and progress over time, and access a comprehensive library of longevity and health-related content.  In addition, a CORE membership grants individuals access to additional a la carte diagnostic testing to detect asymptomatic cardiac disease, cancer, neurodegenerative disease and metabolic dysfunction.  Fountain Life centers offer some of the most advanced health diagnostics available today, including AI-enhanced Full-Body and Brain MRI and Coronary CT Angiography.

To learn more about Fountain Life’s new CORE Membership, please head to fountainlife.com/core-membership  

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post Fountain Life Introduced Fountain Life CORE first appeared on AI-Tech Park.